IP Verse

Pharmaceutical Compositions For The Treatment Of Cystic Fibrosis Transmembrane Conductance Regulator Mediated Diseases - EP3925607

The patent EP3925607 was granted to Vertex Pharmaceuticals Incorporated on Jul 16, 2025. The application was originally filed on Apr 14, 2015 under application number EP21175519A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3925607

VERTEX PHARMACEUTICALS INCORPORATED
Application Number
EP21175519A
Filing Date
Apr 14, 2015
Status
Granted And Under Opposition
May 26, 2023
Grant Date
Jul 16, 2025
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GENERICS UKMar 28, 2024TER MEER STEINMEISTER & PARTNERADMISSIBLE

Patent Citations (45) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONWO2062US59287-
DESCRIPTIONUS2003144257
DESCRIPTIONUS2004006237
DESCRIPTIONUS2004105820
DESCRIPTIONUS2005164973
DESCRIPTIONUS2006035943
DESCRIPTIONUS2006148863
DESCRIPTIONUS2006148864
DESCRIPTIONUS2009131492
DESCRIPTIONUS2013316981
DESCRIPTIONUS6992096
DESCRIPTIONUS7202262
DESCRIPTIONUS8247436
DESCRIPTIONWO0152902
DESCRIPTIONWO2004028480
DESCRIPTIONWO2004080972
DESCRIPTIONWO2004091502
DESCRIPTIONWO2004110352
DESCRIPTIONWO2004111014
DESCRIPTIONWO2005035514
DESCRIPTIONWO2005049018
DESCRIPTIONWO2005094374
DESCRIPTIONWO2005120497
DESCRIPTIONWO2006044456
DESCRIPTIONWO2006044502
DESCRIPTIONWO2006044503
DESCRIPTIONWO2006044505
DESCRIPTIONWO2006044682
DESCRIPTIONWO2006099256
DESCRIPTIONWO2006101740
DESCRIPTIONWO2006110483
DESCRIPTIONWO2006127588
DESCRIPTIONWO2007044560
DESCRIPTIONWO2011113894
OPPOSITIONUS10646481
OPPOSITIONWO2007079139
OPPOSITIONWO2010019239
OPPOSITIONWO2011019413
OPPOSITIONWO2011119984
OPPOSITIONWO2013185112
OPPOSITIONWO2014014841
OPPOSITIONWO2015160787
SEARCHWO2011119984
SEARCHWO2013185112
SEARCHWO2014014841

Non-Patent Literature (NPL) Citations (19) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- "Atomization and Spray-Drying", MARSHALL, Chem. Eng. Prog. Monogr, (19540000), vol. 50-
DESCRIPTION- CUTTING, G. R et al., Nature, (19900000), vol. 346, pages 366 - 369-
DESCRIPTION- DALEMANS et al., Nature Lond, (19910000), vol. 354, pages 526 - 528-
DESCRIPTION- DEAN, M. et al., Cell, (19900000), vol. 61, no. 863, page 870-
DESCRIPTION- GUAY et al., Bioorg. Med. Chem. Lett., (19980000), vol. 8, pages 453 - 458-
DESCRIPTION- KEREM, B-S et al., Proc. Natl. Acad. Sci. USA, (19900000), vol. 87, pages 8447 - 8451-
DESCRIPTION- KEREM, B-S. et al., Science, (19890000), vol. 245, pages 1073 - 1080-
DESCRIPTION- PASYKFOSKETT, J. Cell. Biochem., (19950000), vol. 270, pages 12347 - 50-
DESCRIPTION- QUINTON, P. M., FASEB J., (19900000), vol. 4, pages 2709 - 2727-
DESCRIPTION- VAN GOOR, F.HADIDA S.GROOTENHUIS P., "Pharmacological Rescue of Mutant CFTR function for the Treatment of Cystic Fibrosis", Top. Med. Chem., (20080000), vol. 3, pages 91 - 120, XP009150166-
OPPOSITION- Anonymous, "Kalydeco ivacaftor (EMA/473279/2012)", Assessment report, Committee for Medicinal Products for Human Use (CHMP); European Medicines Agency, (20120806), pages 1 - 87, Assessment report , URL: https://www.ema.europa.eu/en/documents/assessment-report/kalydeco-epar-public-assessment-report_en.pdf, XP093180582-
OPPOSITION- Anonymous, "Kalydeco ivacaftor (EMA/CHMP/311973/2012 )", Summary of opinion1 (initial authorisation), Committee for Medicinal Products for Human Use (CHMP); European Medicines Agency, (20120524), pages 1 - 2, Summary of opinion1 (initial authorisation), URL: https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-kalydeco_en.pdf, XP093180574-
OPPOSITION- D11: Decision of the European Commission to grant a marketing authorisation for Symkevi®, Summary of Product Characteristics for Symkevi®, and European Medicines Agency Assessment Report for Symkevi®.-
OPPOSITION- D14: Decision of the Opposition Division relating to EP 3131582 B1, dated 10th March 2021-
OPPOSITION- D15: DECISION T0569 21, ISSUED ON EP3131582-
OPPOSITION- D16 - Minutes of oral proceedings underlying T 0569/21-
OPPOSITION- Oiu Yihong Yihong, Yitheng Chen, Geoff G., Zhang Z, "Compression and Encapsulation", Developing Solid Oral Dosage Forms Pharmaceutical Theory and Practice, Elsevier, (20090101), page 120, XP093269659-
OPPOSITION- DATTA, S., GRANT, D.J.W., "Crystal Structures of Drugs: Advances in Determination, Prediction and Engineering", Nature Reviews. Drug Discovery, Nature Publishing Group, GB, GB , (20040101), vol. 3, no. 1, doi:10.1038/nrd1280, ISSN 1474-1784, pages 42 - 57, XP009079167
SEARCH- "Study of VX-661 Alone and in Combination With VX-770 in Subjects Homozygous to the F508del-CFTR Mutation", INTERNET CITATION, (20130718), pages 1 - 4, URL: http://clinicaltrials.gov/archive/NCT01531673/2013_07_18, (20140908), XP002729415 [A] 1-30 * the whole document *-

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents